High-througput Functional and Morphological Neurotoxicity Screening in Human NerveSim® Tyler C. Rodriguez¹ , Neki Patel⁵ , Mattia Cocco⁵ , Luke Masterson⁵, Jay Harper⁶, Megan Terral¹, Eva Schmidt¹ , Lowry Curley¹, **AxoSim** Michael J. Moore¹²³, Edward Spack¹, Catherine Rodger⁴, Mary Mcfarlane⁴, and Corey Rountree¹ ¹AxoSim Inc, New Orleans, LA, USA; ²Dept. of Biomedical Engineering, Tulane University, New Orleans, LA, USA; ³Brain Institute, Tulane University, New Orleans, LA, USA; Human Data, Faster. ⁴Oncology Safety, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, UK; ⁵Tumor Targeted Delivery, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA

AxoSim has developed a novel microphysiological human Nerve-on-a-Chip system, or that forms a morphological and electrophysiological simulacrum

Electrode Array (EEA) culture plate to rization amenable to testing dimensional non-invasive longitudinal functional characterizatio







dosing with 100 nM Vincristine, the bundles are no longer visible and significant fragment of neurites is present (arrowheads, E). Quantification of degeneration is done by comparing changes to the same slice, well, and plate

3782/P275



	Class	Modality	VDI IC50	Deg.In IC50	Fib.L IC50	Fib.C IC50
Vincristine	Vinca	Small molecule	1.01 nM	5.45 nM	5.39 nM	7.43 nM
Vinblastine	Vinca	Small molecule	14.4 nM	50.5 nM	29.2 nM	25.8 nM
DM4-SMe	Maytansinoid	Payload	2.42 nM	10.9 nM	7.8 nM	6.42 nM
TDM1	Maytansinoid	ADC	3.9 µg/mL	OoR	OoR	7.69 µg/mL
Sutro Hemi	Hemiasterlin	Payload	3.53 nM	13.5 nM	7.15 nM	29.1 nM
Novel-MTI	NA	Payload	7.24 nM	8.52 nM	6.02 nM	13.5 nM
MMAF	Auristatin	Payload	65.2 nM	379.7 nM	401 nM	629.6 nM
MMAE	Auristatin	Payload	0.46 nM	2.55 nM	3.94 nM	1.85 nM
HER2-MMAE	Auristatin	ADC	4.61 µg/mL	OoR	OoR	OoR
Tubulysin	Tetrapeptide	ADC	NA	NA	NA	NA
Acetaminophen	Analgesic	Control	NA	NA	NA	NA

- elevated for both 2 days after dosing. MMAE at its highest concentration was significantly elevated in LDH at DIV 50.
- HER2-MMAE had a similar electrophysiology IC50 to T-DM1 (4.61 μg/mL and 3.9 μg/mL respectively) with both having
- T-DM1 (trastuzumab emtansine) electrophysiology IC50 was ~ 10 fold higher than the maytansinoid payload DM4-SMe (3.9 μg/mL or 26.8 nM vs 2.42 nM). Growth IC50 for T-DM1 exceeded dose range while DM4-SMe growth IC50 was 7.8
- Tubulysin nearly abolished all electrophysiological activity at 100 nM and caused a significant decrease in fiber length.
- Sutro Hemi had a potent electrophysiology IC50 of 3.53 nM. Degeneration index and fiber length were comparable at 13.5 nM and 7.15 nM respectively. Fiber count was ~10 fold higher than electrophysiology at 29.1 nM which may reflect
- The Novel MTI was also neurotoxic, with an electrophysiology IC50 of 7.24 nM and comparable potency via degeneration metrics.